97110 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
Sub-classes:DUAL CYTOKINE FUSION PROTEINS COMPRISING MULTI-SUBUNIT CYTOKINES
#2IL-10 VARIANT MOLECULES AND METHODS FOR TREATING INFLAMMATORY DISEASE AND ONCOLOGY
#3BETACORONAVIRUS mRNA VACCINES
#4BETACORONAVIRUS mRNA VACCINES
#5ANTIBODY GENE THERAPY FOR TREATMENT AND PREVENTION OF INFECTION BY RABIES LYSSAVIRUS
#6ANTI-DENV3 ANTIBODIES
#7HUMAN METAPNEUMOVIRUS ANTIBODIES AND USES THEREOF
#8ANTIBODIES AND METHODS FOR TREATMENT OF LYSSAVIRUS INFECTION
#9ANTI-RESPIRATORY SYNCYTIAL VIRUS NEUTRALIZING ANTIBODY AND USE THEREOF
#10STABLE FORMULATIONS FOR ANTIBODIES
#11ANTIBODIES THAT NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOF
#12EPITOPE AND IMMUNOGEN DESIGN FOR DEVELOPMENT OF VACCINES, DIAGNOSTICS, AND IMMUNOTHERAPEUTICS
#13BISPECIFIC ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE
#14GP38-Targeting Monoclonal Antibodies Protect Adult Mice Against Lethal Crimean-Congo Hemorrhagic Fever Virus Infection
#15ANTIBODIES OR ANTIBODY-FRAGMENTS THEREOF TARGETING ALPHAVIRUSES, AND COMPOSITIONS AND METHODS COMPRISING SAME
#16COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES
#17Monoclonal Antibody A38 Against Rift Valley Fever Virus and Use
#18NOVEL FISH TOTIVIRUS
#19COTTON LEAFROLL DWARF VIRUS-BINDING ANTIBODIES AND USES THEREOF
#20ANTIBODY COMPOSITIONS AND OPTIMIZATION METHODS
#21NANOSTRUCTURED LIPID CARRIERS AND STABLE EMULSIONS AND USES THEREOF
#22HMPV ANTIBODIES AND THEIR USE
#23NON-INTEGRATING VIRAL DELIVERY SYSTEM AND METHODS RELATED THERETO
#24ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF
#25DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10
#26INFLUENZA VIRUS HEMAGGLUTININ MUTANTS
#27BETACORONA VIRUS mRNA VACCINES
#28BETACORONAVIRUS mRNA VACCINES
#29ANTIBODIES TARGETING MARBURGVIRUS GLYCOPROTEINS AND USES THEREOF
#30COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN INFECTION
#31NON-INTEGRATING VIRAL DELIVERY SYSTEM AND METHODS RELATED THERETO
#32TARGETED DRUG DELIVERY-RELEASE AND KILLING OF DRUG RESISTANT TUMORS AND PATHOGENS
#33PHARMACEUTICAL FORMULATION COMPRISING BISPECIFIC ANTIBODY AGAINST RABIES VIRUS G PROTEIN AND PREPARATION METHOD THEREFOR
#34OPTIMIZED NUCLEIC ACID ANTIBODY CONSTRUCTS
#35DUAL CYTOKINE FUSION PROTEINS COMPRISING MULTI-SUBUNIT CYTOKINES
#36Anti-Human Astrovirus Antibodies and Related Compositions and Methods
#37ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CONONAVIRUS SARS-COV-2
#38IMMUNOGENIC TRIMERS
#39Antibodies to Andes Hantavirus, and Methods for Using Same
#40Chimeric Antigen Receptor-Modified NK-92 Cells
#41FORMULATIONS OF ANTIBODY MOLECULES TO DENGUE VIRUS
#42COMBINATION HMPV/RSV RNA VACCINES
#43Betacoronavirus RNA vaccines
#44ARENAVIRUS MONOCLONAL ANTIBODIES AND USES
#45COMBINATION HMPV/RSV RNA VACCINES
#46METHODS FOR OBTAINING ANTIBODY MOLECULES WITH HIGH AFFINITY
#47COMBINATION HMPV/RSV RNA VACCINES
#48ANTIBODIES THAT BIND METAPNEUMOVIRUS, ANTIGENIC METAPNEUMOVIRUS PROTEINS, AND USES THEREOF
#49Human antibodies to ebola virus glycoprotein
#50METHODS FOR ENHANCING ANTIBODY PRODUCTIVITY IN MAMMALIAN CELL CULTURE AND MINIMIZING AGGREGATION DURING DOWNSTREAM, FORMULATION PROCESSES AND STABLE ANTIBODY FORMULATIONS OBTAINED THEREOF
#51ANTI-HENIPAVIRUS MONOCLONAL ANTIBODY HAVING BROAD SPECTRUM NEUTRALIZATION ACTIVITY AND USE THEREOF
#52HUMAN ANTIBODIES TO CRIMEAN CONGO HEMORRHAGIC FEVER VIRUS
#53ANTIBODY COCKTAIL FOR TREATMENT OF EBOLAVIRUS INFECTIONS
#54HYBRIDOMA CELL LINE FOR SECRETING ANTI-RABIES VIRUS M PROTEIN MONOCLONAL ANTIBODY AND APPLICATION THEREOF
#55MONOCLONAL ANTIBODY 2G1 FOR BROAD-SPECTRUM NEUTRALIZATION OF EBOLA VIRUSES AND APPLICATION THEREOF
#56VACCINES AGAINST RESPIRATORY DISEASES
#57ANTI-NOROVIRUS ANTIBODY
#58NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE
#59Combination of PVY monoclonal antibodies capable of recognizing different antigenic determinants, and use thereof
#60Chimeric Antigen Receptor-Modified NK-92 Cells
#61Antibody specific to spike protein of SARS-CoV-2 and uses thereof
#62COMBINATION OF NOVEL VACCINES AGAINST ZIKA VIRUS AND DNA ANTIBODY CONSTRUCTS FOR USE AGAINST ZIKA VIRUS
#63LASSA VIRUS-SPECIFIC NANOBODIES AND METHODS OF THEIR USE
#64Anti-yellow fever virus antibodies, and methods of their generation and use
#65SYSTEMS AND PROCESSES TO SCREEN FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) OF 2019 (COVID-19)
#66METHODS AND COMPOSITIONS FOR INDUCIBLE EXTRACELLULAR MEMBRANE CAPTURE OF MONOCLONAL IMMUNOGLOBULINS SECRETED BY HYBRIDOMAS
#67ANTIBODIES FOR SARS-COV-2 AND USES THEREOF
#68SARS-COV-2 ANTIBODIES AND METHODS OF SELECTING AND USING THE SAME
#69ANTI-RSV ANTIBODY AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
#70UNIVERSAL TARGETING STRATEGY TO INHIBIT REPLICATION OF ZIKV AND FLAVIVIRUSES
#71MESOPOROUS NITRIC OXIDE-RELEASING SILICA PARTICLES, METHODS OF MAKING, AND USES THEREOF
#72NS1-BINDING PROTEIN
#73SPECIES OF TOBAMOVIRUS
#74Neutralizing Anti-SARS-CoV-2 Antibodies and Methods of Use Thereof
#75Anti-coronavirus antibodies and methods of use
#76CORONAVIRUS: EARLY DETECTION AND TREATMENT
#77COMBINATION OF NOVEL VACCINES AGAINST ZIKA VIRUS AND DNA ANTIBODY CONSTRUCTS FOR USE AGAINST ZIKA VIRUS
#78FC-ENHANCED ANTIBODIES FOR PREVENTION AND TREATMENT OF EBOLA VIRUS INFECTION
#79METHOD OF REDUCING THE IMMUNOSTIMULATORY PROPERTIES OF IN VITRO TRANSCRIBED RNA
#80SARS-COV-2 ANTIBODIES FOR TREATMENT AND PREVENTION OF COVID-19
#81Rabies virus monoclonal antibody 2F2 and universal rabies virus antibody rapid detection test paper
#82Dual cytokine fusion proteins comprising IL-10
#83Dual cytokine fusion proteins comprising IL-10
#84Dual cytokine fusion proteins comprising IL-10
#85Dual cytokine fusion proteins comprising IL-10
#86Dual cytokine fusion proteins comprising IL-10
#87ANTIBODY COCKTAIL AGAINST SARS-COV-2 SPIKE PROTEIN
#88Dual cytokine fusion proteins comprising IL-10
#89Dual cytokine fusion proteins comprising IL-10
#90Dual cytokine fusion proteins comprising IL-10
#91Dual cytokine fusion proteins comprising IL-10
#92Dual cytokine fusion proteins comprising IL-10
#93SYSTEMS AND METHODS TO LINK CD40 SIGNALING TO ANTIGEN BINDING
#94ANTIBODIES THAT POTENTLY NEUTRALIZE RABIES VIRUS AND OTHER LYSSAVIRUSES AND USES THEREOF
#95Biological Therapeutics for Infection-Relating Disorders or Conditions
#96COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY
#97METHODS FOR QUANTITATING INDIVIDUAL ANTIBODIES FROM A MIXTURE
#98ANTIVIRAL AGENTS
#99ANTI-RSV MONOCLONAL ANTIBODY FORMULATION
#100REPAIRED THERAPEUTIC AND PROPHYLACTIC ANTIBODIES AGAINST SARS-CoV-2 VARIANTS
#101COVID-19 ANTIBODIES AND USES THEREOF
#102Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
#103DNA ANTIBODY CONSTRUCTS FOR USE AGAINST ROTAVIRUS
#104HEPATITIS E VIRUS ORF2 CAPSID POLYPEPTIDES AND USES THEREOF
#105SHARK-DERIVED BINDING MOLECULES FOR SARS-COV-2 CORONAVIRUS AND USES THEREOF
#106SARS-COV-2 spike protein binding molecule and application thereof
#107ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USING THE SAME
#108METHOD FOR DETECTION OF ZIKA VIRUS SPECIFIC ANTIBODIES
#109ANTIBODY FOR PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND USES THEREOF
#110IMMUNOGENS DERIVED FROM SARS-COV2 SPIKE PROTEIN
#111MULTIMERIC ANTIBODY PLATFORM AND METHODS OF MAKING AND USING MULTIMERIC ANTIBODY PLATFORM
#112HUMAN ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AGAINST CORONAVIRUS SPIKE PROTEIN
#113CORONAVIRUS POINT-OF-CARE AGGLUTINATION ASSAY
#114Ebola Virus Antibodies and Binding Agents Derived Therefrom
#115CELL-FREE ANTIBODY ENGINEERING PLATFORM AND NEUTRALIZING ANTIBODIES FOR SARS-COV-2
#116MODIFIED ANTI-VIRAL BINDING AGENTS
#117THERAPEUTIC AND DIAGNOSTIC VHH ANTIBODIES AGAINST SARS-COV-2 AND METHODS FOR THEIR ENHANCEMENT
#118Antibodies that potently neutralize hepatitis B virus and uses thereof
#119Fusion Molecules of PSGL-1 or TSGL Anionic Domains to Checkpoint-Modulating Antibodies and Other Antibodies
#120ANTIBODY FOR PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND USES THEREOF
#121Antigen binding molecules targeting SARS-CoV-2
#122ANTI-SARS CORONAVIRUS-2 SPIKE PROTEIN ANTIBODIES
#123RNA ENCODING AN ANTIBODY
#124METHODS AND COMPOSITIONS FOR THE GENERATION OF PROGRAMABLE POST-TRANSLATIONAL PROTEIN MODIFICATION AND HYDROLYSIS
#125Antigen binding molecules targeting SARS-CoV-2
#126BINDING AGENTS FOR CORONAVIRUS S PROTEIN
#127THERAPEUTIC AND DIAGNOSTIC VHH ANTIBODIES AGAINST SARS-COV-2 AND METHODS FOR THEIR ENHANCEMENT
#128CELL-PENETRATING PEPTIDE AND USE THEREOF
#129DUAL CYTOKINE FUSION PROTEINS COMPRISING MULTI-SUBUNIT CYTOKINES
#130METHOD FOR IN VITRO PROLIFERATING VIRUS BELONGING TO FAMILY CORONAVIRIDAE, METHOD FOR PRODUCING NEUTRALIZING ANTIBODY TO VIRUS BELONGING TO FAMILY CORONAVIRIDAE, AND METHOD FOR PRODUCING INFECTION MODEL OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2
#131Antigen Binding Molecules Targeting SARS-CoV-2
#132ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF
#133NOVEL MONOCLONAL ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF
#134SARS-COV-2 PROTEINS, ANTI-SARS-COV-2 ANTIBODIES, AND METHODS OF USING THE SAME
#135METHODS TO BLOCK APHID TRANSMISSION OF POLEROVIRUSES AND TO DEVELOP VIRUS MANAGEMENT TOOLS
#136METHODS AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF CORONAVIRUS INFECTION
#137BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2)
#138HUMAN RECOMBINANT ACE2-FC MUTANTS THAT DECOUPLE ANTI-SARS-COV-2 ACTIVITY FROM CARDIOVASCULAR EFFECTS
#139Antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2
#140Monoclonal antibody for spike protein of middle east respiratory syndrome coronavirus, and use thereof
#141Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Peptide Epitopes
#142METHODS FOR DETECTING A TARGET IN A SAMPLE USING MUTATED NANOBODIES
#143METHOD FOR ANTIGEN DETECTION FROM DIRECT CLINICAL SAMPLES
#144NANOSCALE POLYMERIC MICELLAR SCAFFOLDS FOR RAPID AND EFFICIENT ANTIBODY PRODUCTION
#145BISPECIFIC SARS-COV-2 ANTIBODIES AND METHODS OF USE
#146EFFICIENT EXPRESSION SYSTEM OF SARS-COV-2 RECEPTOR BINDING DOMAIN (RBD), METHODS FOR PURIFICATION AND USE THEREOF
#147Anti-spike glycoprotein antibodies and the therapeutic use thereof
#148ANTIBODIES FOR CORONAVIRUS AND USES THEREOF
#149MULTIMERS FOR VIRAL STRAIN EVOLUTION
#150COMPOSITION AND METHOD FOR ACTIVATING LATENT HUMAN IMMUNODEFICIENCY VIRUS (HIV)
#151COMPOSITION FOR TREATMENT AND PREVENTION OF COVID-19
#152PANDEMIC-PREPAREDNESS COCKTAIL TO FIGHT CORONAVIRUS OUTBREAKS
#153HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
#154COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF SARS-COV-2 VIRUS INFECTION
#155MONO- AND MULTI-VALENT SARS-COV- 2 ADENOVIRAL VECTOR VACCINES AND SARS-COV-2 IMMUNE GLOBULIN AND METHODS OF USE
#156BROADLY NEUTRALIZING BINDING MOLECULES AGAINST MARBURGVIRUSES
#157ANTIBODY AGAINST SARS-COV-2, METHOD FOR DETECTING SARS-COV-2 USING ANTIBODY AND KIT CONTAINING ANTIBODY
#158NANOBODIES DIRECTED TO CORONAVIRUS SPIKE PROTEIN RECEPTOR BINDING DOMAIN AND USES THEREOF
#159INFECTIOUS DISEASE ANTIBODIES AND USES THEREOF
#160METHODS AND COMPOSITIONS RELATED TO NEUTRALIZING ANTIBODIES AGAINST HUMAN CORONAVIRUS
#161SARS-COV2 NEUTRALIZING SINGLE DOMAIN ANTIBODY CONSTRUCTS
#162CORONA VIRUS BINDERS
#163Fatty Acid Complexes Of Coronavirus Spike Protein And Their Use
#164ANTI-CORONAVIRUS ANTIBODIES AND USES THEREOF
#165ANTI-SARS-CoV-2 ANTIBODIES AND USES THEREOF
#166IGA ANTIBODY SPECIFICALLY RECOGNIZING RBD PROTEIN AND TESTING KIT
#167Peptide Therapeutics Against SARS-COV-2 Spike Protein
#168MULTIPLE RAPID DETECTION KITS AND METHODS FOR VARIOUS VIRUSES
#169Filovirus antibodies and methods
#170DNA ANTIBODY CONSTRUCTS FOR USE AGAINST SARS-COV-2
#171NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST COVID19
#172SARS-CoV-2 Vaccines and Antibodies
#173SARS-COV-2-SPECIFIC T CELLS
#174ACE2 RECEPTOR POLYMORPHISMS AND VARYING SUSCEPTIBILITY TO SARS-COV-2, METHODS FOR DIAGNOSIS AND TREATMENT
#175PREPARATION METHOD OF ARTIFICIAL ANTIBODY
#176ANTI-YELLOW FEVER VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE
#177POTENT NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2, GENERATION AND USES THEREOF
#178BLOCKING ELISA KIT FOR DETECTING ANTIBODY TO SWINE ACUTE DIARRHEA SYNDROME CORONAVIRUS N PROTEIN
#179POLYPEPTIDES ENCODING ANTIBODIES BINDING TO SARS-COV-2 SPIKE PROTEIN
#180ANTI-SARS-COV-2 SPIKE PROTEIN ANTIBODIES AND METHODS OF USE
#181SINGLE DOMAIN ANTIBODIES FOR SARS-COV-2
#182SARS-COV-2 ANTIBODIES AND RELATED COMPOSITIONS AND METHODS OF USE
#183ANTIBODY THAT BINDS SPECIFICALLY TO THE SARS COV 2 SPIKE PROTEIN, AND METHODS FOR ITS MANUFACTURE
#184INFECTIOUS BRONCHITIS (IB) VIRUS VARIANTS AND RELATED COMPOSITIONS, USES AND METHOD
#185METHODS FOR PREVENTING, REVERSING OR TREATING A COVID-19 INFECTION
#186METHOD FOR PREPARING ANTIGEN-BINDING UNIT
#187CMV VACCINES
#188DETECTION ASSAY FOR SARS-COV-2 VIRUS
#189ANTI-NOVEL CORONAVIRUS MONOCLONAL ANTIBODY AND APPLICATION THEREOF
#190ANTIBODIES TO SUDAN AND EBOLA VIRUS
#191RECOMBINANT ANTIBODIES, KITS COMPRISING THE SAME, AND USES THEREOF
#192TARGETED THERAPY FOR THE TREATMENT & PREVENTION OF LIFE-THREATENING COMPLICATIONS OF INFECTION
#193CALIBRATION AND QUALITY CONTROL REAGENTS FOR USE WITH IMMUNOASSAYS FOR ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF
#194METHODS FOR IDENTIFYING CORONAVIRUS CROSS-REACTING ANTIBODIES
#195TREATING OR PREVENTING TRAVELERS DIARRHEA
#196COMPOSITIONS FOR PREVENTING OR TREATING VIRAL AND OTHER MICROBIAL INFECTIONS
#197METHODS TO PREVENT SARS-COV-2 INFECTION AND TREAT COVID-19
#198Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
#199CROSS-REACTIVE ANTIBODIES AND USES THEREOF
#200HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
#201Methods for quantitating individual antibodies from a mixture
#202MONOCLONAL ANTIBODY AGAINST NOVEL CORONAVIRUS AND APPLICATION THEREOF
#203SARS-COV-2 SPIKE PROTEIN ANTIBODIES
#204BINDING MOLECULE HAVING NEUTRALIZING ACTIVITY AGAINST SARS-CORONAVIRUS-2
#205DESIGNER PEPTIDES AND PROTEINS FOR THE DETECTION, PREVENTION AND TREATMENT OF CORONAVIRUS DISEASE, 2019 (COVID-19)
#206Antibody specific to spike protein of SARS-CoV-2 and uses thereof
#207ANTIBODIES THAT BIND HUMAN METAPNEUMOVIRUS FUSION PROTEIN AND THEIR USE
#208HUMAN ANTIBODIES THAT NEUTRALIZE ZIKA VIRUS AND METHODS OF USE THEREFOR
#209Efficient expression system of SARS-CoV-2 receptor binding domain (RBD), methods for purification and use thereof
#210ANTIGEN-BINDING PROTEINS TARGETING CORONAVIRUS (COV) VARIANTS
#211HUMANIZED MONOCLONAL ANTIBODY FOR 2019 NOVEL CORONAVIRUS AND USE THEREOF
#212HUMAN ANTIBODIES TO ALPHAVIRUSES
#213HUMAN ANTIBODIES TO RIFT VALLEY FEVER VIRUS
#214MULTIMERIC CORONAVIRUS BINDING MOLECULES AND USES THEREOF
#215NEUTRALIZING MONO-SPECIFIC IgY ANTIBODIES TO INHIBIT OR TREAT SARS-COV-2 CORONAVIRUS INFECTION
#216Monoclonal antibodies and cocktails for treatment of Ebola infections
#217COMPOSITIONS AND METHODS RELATED TO SURGE-ASSOCIATED SARS-COV-2 MUTANTS
#218Recombinant antibody and uses thereof
#219Rapid assay for detection of SARS-CoV-2 antibodies
#220Norovirus fusion proteins and VLPs comprising norovirus fusion proteins
#221IMMUNOGENIC TRIMERS
#222Methods and compositions relating to covid antibody epitopes
#223METHOD FOR TREATING INFECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)
#224ANTI-CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE
#225ATTENUATED AVIAN REOVIRUS STRAINS 94826 C140 AND 97139 C140
#226MULTIMERIC CORONAVIRUS BINDING MOLECULES AND USES THEREOF
#227Compositions and methods for the treatment of immunodeficiency
#228Chimeric antigen receptor-modified NK-92 cells
#229HUMAN MONOCLONAL ANTIBODIES TO HANTAVIRUS AND METHODS OF USE THEREFORE
#230Dual cytokine fusion proteins comprising IL-10
#231Dual cytokine fusion proteins comprising IL-10
#232SARS-COV-2 SPIKE PROTEIN ANTIBODIES
#233NANO ANTIBODY FOR NEUTRALIZING TOXICITY OF SARS-COV-2 AND PREPARATION METHOD AND APPLICATION THEREOF
#234Methods of optimizing nucleotide sequences encoding engineered influenza proteins
#235Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
#236Anti-Coronavirus Antibodies and Methods of Use
#237GALECTIN-TARGETING IMMUNOTHERAPY
#238Dual cytokine fusion proteins comprising IL-10
#239HUMANIZED ANTIBODY FOR SARS-CoV-2 SPIKE PROTEIN INFUSION
#240ZIKA ANTIBODIES AND THEIR USE
#241Antibodies to Andes hantavirus, and methods for using same
#242HUMAN MONOCLONAL ANTIBODIES TO ENTEROVIRUS D68
#243NEUTRALIZING ANTIBODIES TO SARS-COV-2 AND ITS VARIANTS
#244Rabies vaccine
#245Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
#246Dual cytokine fusion proteins comprising IL-10
#247Dual cytokine fusion proteins comprising IL-10
#248Dual cytokine fusion proteins comprising IL-10
#249MULTIMERIC SARS-COV-2 BINDING MOLECULES AND USES THEREOF
#250Dual cytokine fusion proteins comprising IL-10
#251A METHOD OF TREATING HBV INFECTION BY USING ANTI-PRE-S1 HBV ANTIBODIES
#252FABRICATION OF PROTEIN-ENCAPSULATING MICROGELS
#253HYBRIDOMA, METHOD FOR MAKING THE SAME, MONOCLONAL ANTIBODY, AND METHOD FOR MAKING THE SAME
#254Anti-spike glycoprotein antibodies and the therapeutic use thereof
#255METHOD FOR DETECTION OF MERS-COV WITH IGY ANTIBODIES
#256Amino acid sequence derived from S protein of SARS-CoV2 for generating an anti-SARS-CoV-2 antibody
#257Antibody cocktail against SARS-CoV-2 spike protein
#258Neutralizing anti-SARS-CoV-2 antibodies
#259CORONAVIRUS-BINDING MOLECULES AND METHODS OF USE THEREOF
#260CLEAVING PRE-FUSION STATE SARS-COV-2 SPIKE PROTEIN
#261Multi-specific antibodies for cross-neutralization of multiple filovirus glycoproteins
#262Rapid assay for detection of SARS-CoV-2 antibodies
#263ANTIBODIES AGAINST SARS-COV-2 SPIKE PROTEIN
#264CORONAVIRUS: EARLY DETECTION AND TREATMENT
#265METHODS AND SYSTEMS FOR DETECTING CORONAVIRUS
#266ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF
#267Antibody-based blockage of SARS-CoV-2-specific furin cleavage site
#268Neutralizing anti-SARS-CoV-2 antibodies
#269S309 chimeric antigen receptors and methods of use
#270Binding Molecule Having Neutralizing Activity Against Middle East Respiratory Syndrome-Coronavirus
#271ENGINEERED ANTIBODIES
#272TEST KITS, DEVICES AND METHODS FOR DETECTING INFECTION
#273Systems and Methods for the Production of Human Polyclonal Antibodies
#274COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF
#275DENGUE VIRUS NON-STRUCTURAL PROTEIN 1 SPECIFIC BINDING POLYPEPTIDES AND METHODS OF USING THE SAME
#276NEUROPILIN ANTIBODY NASAL SPRAY TO REDUCE COVID-19 TRANSMISSION
#277Single domain antibodies to SARS-CoV-2 nucleocapsid protein
#278Intranasal Antiviral Therapy for Mucosal Protection Against Virus Infections
#279Anti-Viroporin Antibodies and Methods of Treating COVID-19
#280Antibodies that neutralize hepatitis B virus and uses thereof
#281Compositions for preventing or treating viral and other microbial infections
#282DNA Antibody Constructs And Method Of Using Same
#283DNA antibody constructs for use against middle east respiratory syndrome coronavirus
#284SIN NOMBRE VIRUS FULL-LENGTH M SEGMENT-BASED DNA VACCINES
#285ARENAVIRUS MONOCLONAL ANTIBODIES AND USES
#286Targeting SARS-CoV-2 Viral-immune Interaction for COVID-19 Therapy
#287EBOLA VIRUS GLYCOPROTEIN-SPECIFIC MONOCLONAL ANTIBODIES AND USES THEREOF
#288Nano-antibody and its application based on SARS-CoV-2 S protein
#289Nano-antibody and its application based on SARS-CoV-2 S protein S1 subunit
#290ANTI-SARS-COV-2 ANTIBODIES AND APPLICATION THEREOF
#291Anti-SARS-CoV-2 neutralizing antibodies
#292TREATMENT OF VIRAL INFECTION BY APHERESIS
#293ANTIBODIES AND METHODS FOR TREATMENT OF LYSSAVIRUS INFECTION
#294Cleaving pre-fusion state SARS-CoV-2 spike protein
#295Episomal Expression of Potent Immunoglobulins Derived from Human Blood or Convalescent Plasma to Enable Short term Vaccination / Immunization to COVID, COVID-19 and Mutants and Other Pandemic and non-Pandemic Viruses designed from Rapid FDA approval.
#296GP38-TARGETING MONOCLONAL ANTIBODIES PROTECT ADULT MICE AGAINST LETHAL CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS INFECTION
#297MONOCLONAL ANTIBODIES AGAINST SARS-CoV-2 NUCLEOCAPSID PROTEIN AND USES THEREOF
#298MONOCLONAL ANTIBODY AGAINST SPIKE S1 PROTEIN OF SARS-CoV-2 AND USE THEREOFOF
#299Nanostructured lipid carriers and stable emulsions and uses thereof
#300CR3022 chimeric antigen receptors and methods of use